Yes, PMDD is officially classified as a mood disorder. The DSM-5, which is the standard diagnostic manual used in psychiatry, lists premenstrual dysphoric disorder in its Mood Disorders section. This classification wasn’t always the case. PMDD spent decades in a kind of diagnostic limbo before earning its current status, and its recognition as a legitimate mood disorder has shaped how it’s understood, treated, and taken seriously.
How PMDD Earned Its Classification
PMDD’s path into the mood disorders category was a slow one. It first appeared in the late 1980s under the name “late luteal phase dysphoric disorder,” tucked into an appendix of the DSM-III-R reserved for conditions needing more study. When the DSM-IV came out, the condition was renamed premenstrual dysphoric disorder, but it stayed in the appendix. The work group at the time felt more research was needed to confirm that PMDD was truly distinct from other disorders.
By the time the DSM-5 was published in 2013, decades of evidence on PMDD’s biology, prevalence, and treatment response had accumulated. The American Psychiatric Association’s work group concluded that the science had matured enough for PMDD to be promoted from an appendix listing to a full diagnostic category within the Mood Disorders section. That move gave the condition greater clinical legitimacy and made it easier for people to receive a formal diagnosis and appropriate treatment.
What Makes PMDD Different From PMS
PMDD is not simply a severe version of premenstrual syndrome, though the two share timing and some overlapping symptoms. The key distinction is that PMDD’s core features are psychiatric: depressed mood, intense anxiety, severe irritability, and mood swings that significantly disrupt daily life. Physical symptoms like bloating, breast tenderness, and headaches can occur alongside these, but the emotional and behavioral symptoms are what define the disorder and drive its classification as a mood condition.
To meet the diagnostic criteria, you need at least five symptoms present in the week before your period that resolve within a few days after menstruation starts. This pattern must be confirmed across most menstrual cycles over the course of a year. The symptoms also have to be severe enough to interfere with work, relationships, or daily functioning. Prospective tracking, meaning recording symptoms daily for at least two cycles rather than recalling them from memory, is considered the gold standard for diagnosis.
The Biology Behind PMDD
One of the most important things to understand about PMDD is that it’s not caused by abnormal hormone levels. People with PMDD have the same estrogen and progesterone levels as everyone else. The difference is in how their brains respond to the normal hormonal fluctuations that happen after ovulation.
Research points to a hypersensitivity to these hormonal shifts, particularly involving a substance called allopregnanolone. This is a byproduct of progesterone that normally has a calming effect on the brain by acting on the same receptors targeted by anti-anxiety medications. In people with PMDD, these receptors appear to function differently. Studies have found decreased sensitivity to calming compounds and an altered response to allopregnanolone at the concentrations typically present during the second half of the menstrual cycle. In animal models, this receptor change is linked to increased anxiety.
The serotonin system is also involved. Estrogen and progesterone influence serotonin levels, and in people with PMDD, the brain’s handling of these changes appears dysregulated. Research from the Max Planck Institute found that shortly before menstruation, the brain ramps up production of a protein that pulls serotonin out of the spaces between nerve cells. The result is less serotonin available for mood regulation, which helps explain why the emotional symptoms hit hardest in the days before a period starts.
How Common PMDD Is
A 2024 meta-analysis of 44 studies covering more than 50,000 participants found that about 3.2% of menstruating people meet confirmed diagnostic criteria for PMDD. When the analysis was limited to community-based samples with the strictest diagnostic methods, that number dropped to 1.6%. A larger figure of roughly 7.7% appears when provisional diagnoses (those not confirmed by prospective tracking) are included. These numbers mean PMDD affects millions of people worldwide, though it remains underdiagnosed.
The Severity of PMDD Symptoms
PMDD carries serious mental health risks that set it apart from ordinary premenstrual discomfort. A large survey of over 3,700 women with PMDD found that 82% had experienced suicidal thoughts during the luteal phase on at least one occasion. Nearly half reported having deliberately harmed themselves during a PMDD crisis. And 26% had attempted suicide, with 13% having made more than one attempt.
These numbers underscore why the mood disorder classification matters. PMDD is cyclical, meaning symptoms resolve after menstruation, but the severity during the symptomatic window can be life-threatening. The predictable return of these episodes each month creates a cumulative burden on mental health, relationships, and quality of life.
How PMDD Is Treated
Because PMDD involves serotonin disruption, SSRIs (a class of antidepressant) are the most effective treatment. Interestingly, SSRIs work much faster for PMDD than they do for depression, often providing relief within days rather than weeks. This rapid onset suggests they’re working through a different mechanism than their antidepressant effect, though exactly how remains unclear.
This speed advantage means you don’t necessarily need to take an SSRI every day. Many people use what’s called luteal-phase dosing, taking the medication only during the roughly 14 days between ovulation and the start of menstruation. Intermittent dosing works well for irritability and mood swings. If fatigue or physical symptoms are prominent, daily dosing may be more effective. Sexual side effects like reduced libido can persist even with intermittent use, while nausea tends to fade quickly and doesn’t typically recur between dosing cycles.
Hormonal treatments are also used. The only oral contraceptive with FDA approval specifically for severe premenstrual symptoms is a combination of drospirenone and ethinyl estradiol, marketed as Yaz or Yasmin. It was approved in 2006 and remains the only one with that specific indication. For people who don’t respond to SSRIs or hormonal options, treatments that temporarily suppress ovulation altogether can be considered.
PMDD vs. Premenstrual Exacerbation
One of the trickiest diagnostic challenges is distinguishing PMDD from something called premenstrual exacerbation, or PME. With PMDD, symptoms appear in the luteal phase and disappear after menstruation. You have a clear symptom-free window during the first half of your cycle. With PME, you already have an existing condition (depression, anxiety, bipolar disorder, ADHD) that gets noticeably worse before your period, but symptoms of that condition are present to some degree throughout the entire cycle.
This distinction matters because the treatment approaches differ. If someone with underlying depression is diagnosed with PMDD when they actually have PME, luteal-phase dosing alone won’t address the persistent baseline symptoms. Prospective daily symptom tracking across at least two full cycles is the most reliable way to tell the two apart, since retrospective recall tends to be inaccurate. If you suspect your premenstrual symptoms might reflect a worsening of something already present, consistent daily tracking will clarify the pattern.